Corrigendum: Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center

Dániel Deme,Bálint Ferenc Tamaskovics,Nizar Jammoul,Sándor Kovács,Kmmanuel Oladunjoye Kayode,James W Grice,András Telekes

DOI: https://doi.org/10.3389/pore.2024.1611862

2024-07-08

Abstract:[This corrects the article DOI: 10.3389/pore.2024.1611735.].

What problem does this paper attempt to address?

Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center

Dániel Deme,Bálint Ferenc Tamaskovics,Nizar Jammoul,Sándor Kovács,Emmanuel Oladunjoye Kayode,James W. Grice,András Telekes

DOI: https://doi.org/10.3389/pore.2024.1611735

2024-04-16

Abstract:Introduction: The 21-gene analysis (OncotypeDX) is validated test for pT1-3, pN0-1 with hormone receptor (HR) positive and normal expression of human epidermal growth factor receptor-2 (HER2) breast cancer (BC) to determine the aggressiveness of the disease based on the calculation of Recurrence Score (RS). Methods: In this retrospective study the authors correlated pathological characteristics and Recurrence Score (RS) by traditional statistical methods and Observed Oriented Modeling (OOM) in a realistic cohort of BC patients. Results: OncotypeDX tests were performed in 94 tumour specimens of 90 BC patients. >83% of node-negative (pN0) and >72% of node-positive (pN1) cases could avoid chemotherapy. For pN0 cases, non-parametric correlation and tests demonstrated significant association in eight types of characteristics [progesterone receptor (PR) expression, Ki-67 value, Ki-67 group, PR group, grade, estrogen receptor (ER) expression, Nottingham Prognostic Index (NPI) and Clinical Risk]. For pN1 cases, parametric correlation and tests showed significant association in six characteristic types (number of positive nodes, ER and PR expression, PR group, Ki-67 group and NPI). Based on OOM for pN0 cases, significant associations were established in three characteristics (Ki-67 group, grade and NPI group). For pN1 cases OOM found significant associations in seven characteristics (PR group, PNI, LVI, Ki-67 group, grade, NPI group and number of positive nodes). Conclusion: First in oncology, OOM was applied, which found some other significant characteristics associated with RS than traditional statistical methods. There were few patients, where no clinical associations were found between characteristics and RS contrary to statistically significant differences. Therefore, the results of these statistical analyses can be neither applied for individual cases nor able to provide the bases for screening patients, i.e., whether they need for OncotypeDX testing or not. OncotypeDX still provides a personalised approach in BC.

oncology,pathology
Corrigendum to "re: Pathologic Complete Responses, Long-Term Outcomes, and Recurrence Patterns in HER2-low Vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy: Several Issues about HER2 Expression and Neoadjuvant Chemotherapy in Breast Cancer" [eur J Cancer 180 (2023) 184-185].

Fan Yang,Guanmo Liu,Feng Mao,Yong-Chang Zheng

DOI: https://doi.org/10.1016/j.ejca.2024.113559

2024-01-01

Abstract:The authors regret that an error was made in the detail for affiliation c. The correct affiliation is: Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. The authors would like to apologise for any inconvenience caused. Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancerEuropean Journal of CancerVol. 180PreviewWe followed with interest the report by Sora Kang et al. that pathological complete response (pCR) rate and disease-free survival (DFS) in patients with HER2-low as well as HER2-0 breast cancers who have undergone neoadjuvant chemotherapy [1]. There are many complex factors influencing condition of response and survival of breast cancer after neoadjuvant therapy by the changes of HER2 and hormone receptor (HR) status. We appreciated the authors' work in comparing the prognosis of patients with breast cancer after neoadjuvant chemotherapy in different HER2 status and providing new therapeutic ideas. Full-Text PDF
Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors: A Propensity-Score Matched Cohort Study: Erratum

DOI: https://doi.org/10.1097/as9.0000000000000290

2023-06-01

Annals of Surgery Open

Abstract:[This corrects the article DOI: 10.1097/AS9.0000000000000151.].

English Else
Erratum to "Additional biomarkers for pathological complete response in triple negative breast cancer"

DOI: https://doi.org/10.1177/17588359241290373

2024-10-21

Abstract:[This corrects the article DOI: 10.1177/17588359241267148.].
Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Wen-Jie Wu,Qian Liu,Pu-Gen An,Lin Wang,Jian-Yun Zhang,Yan Chen,Tong Zhang,Jie Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1346845

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1282629.].
Erratum: Preoperative immunological plasma markers TRAIL, CSF1, and TIE2 predict survival after resection for biliary tract cancer

Frontiers Production Office

DOI: https://doi.org/10.3389/fonc.2023.1281693

2023-09-27

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1169537.].
Corrigendum: Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

Haoran Qian,Na Yan,Xiaotong Hu,Junchang Jiang,Zhengzheng Cao,Dan Shen

DOI: https://doi.org/10.3389/fgene.2022.945357

IF: 3.7

2022-06-28

Frontiers in Genetics

Abstract:[This corrects the article DOI: 10.3389/fgene.2022.864499.].

genetics & heredity
Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

TingAn Wang,HuaGe Zhong,YuZhou Qin,WeiYuan Wei,Zhao Li,MingWei Huang,XiaoLing Luo

DOI: https://doi.org/10.1155/2021/3179693

2021-02-09

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2020/3575038.].

biotechnology & applied microbiology,medicine, research & experimental
Corrigendum to "Long recurrence-free survival of localized rectal melanoma after abdominoperineal resection in comparison to partial excision and highlighting the place of immunotherapy: A case report."

DOI: https://doi.org/10.1177/20542704241260192

2024-06-02

JRSM Open

Abstract:[This corrects the article DOI: 10.1177/20542704221148059.].
Corrigendum: Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellular carcinoma

Yongrong Lei,Xishu Wang,Heng Sun,Yuna Fu,Yichen Tian,Ludi Yang,Jianhua Wang,Feng Xia

DOI: https://doi.org/10.3389/fonc.2024.1438731

2024-07-10

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.601668.].
Corrigendum: Whole-genome Landscape of Pancreatic Neuroendocrine Tumours.

Aldo Scarpa,David K Chang,Katia Nones,Vincenzo Corbo,Ann-Marie Patch,Peter Bailey,Rita T Lawlor,Amber L Johns,David K Miller,Andrea Mafficini,Borislav Rusev,Maria Scardoni,Davide Antonello,Stefano Barbi,Katarzyna O Sikora,Sara Cingarlini,Caterina Vicentini,Skye McKay,Michael C J Quinn,Timothy J C Bruxner,Angelika N Christ,Ivon Harliwong,Senel Idrisoglu,Suzanne McLean,Craig Nourse,Ehsan Nourbakhsh,Peter J Wilson,Matthew J Anderson,J Lynn Fink,Felicity Newell,Nick Waddell,Oliver Holmes,Stephen H Kazakoff,Conrad Leonard,Scott Wood,Qinying Xu,Shivashankar Hiriyur Nagaraj,Eliana Amato,Irene Dalai,Samantha Bersani,Ivana Cataldo,Angelo P Dei Tos,Paola Capelli,Maria Vittoria Davì,Luca Landoni,Anna Malpaga,Marco Miotto,Vicki L J Whitehall,Barbara A Leggett,Janelle L Harris,Jonathan Harris,Marc D Jones,Jeremy Humphris,Lorraine A Chantrill,Venessa Chin,Adnan M Nagrial,Marina Pajic,Christopher J Scarlett,Andreia Pinho,Ilse Rooman,Christopher Toon,Jianmin Wu,Mark Pinese,Mark Cowley,Andrew Barbour,Amanda Mawson,Emily S Humphrey,Emily K Colvin,Angela Chou,Jessica A Lovell,Nigel B Jamieson,Fraser Duthie,Marie-Claude Gingras,William E Fisher,Rebecca A Dagg,Loretta M S Lau,Michael Lee,Hilda A Pickett,Roger R Reddel,Jaswinder S Samra,James G Kench,Neil D Merrett,Krishna Epari,Nam Q Nguyen,Nikolajs Zeps,Massimo Falconi,Michele Simbolo,Giovanni Butturini,George Van Buren,Stefano Partelli,Matteo Fassan,Kum,Anthony J Gill,David A Wheeler,Richard A Gibbs,Elizabeth A Musgrove,Claudio Bassi,Giampaolo Tortora,Paolo Pederzoli,John V Pearson,Nicola Waddell,Andrew V Biankin,Sean M Grimmond

DOI: https://doi.org/10.1038/nature24026

IF: 64.8

2017-01-01

Nature

Abstract:This corrects the article DOI: 10.1038/nature21063.
Corrigendum: Predictive value of intratumoral-metabolic heterogeneity derived from 18F-FDG PET/CT in distinguishing microsatellite instability status of colorectal carcinoma

Li Zhang,Yu Liu,Ying Ding,Yinqian Deng,Huanyu Chen,Fan Hu,Jun Fan,Xiaoli Lan,Wei Cao

DOI: https://doi.org/10.3389/fonc.2023.1351842

IF: 4.7

2024-01-05

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1065744.].

oncology
Correction: Ádány et al. Discrepancies Between the Spatial Distribution of Cancer Incidence and Mortality as an Indicator of Unmet Needs in Cancer Prevention and/or Treatment in Hungary. Cancers 2024, 16, 2917

Róza Ádány,Attila Juhász,Csilla Nagy,Bernadett Burkali,Péter Pikó,Martin McKee,Beatrix Oroszi

DOI: https://doi.org/10.3390/cancers16233964

2024-11-28

Cancers

Abstract:Cancers, Vol. 16, Pages 3964: Correction: Ádány et al. Discrepancies Between the Spatial Distribution of Cancer Incidence and Mortality as an Indicator of Unmet Needs in Cancer Prevention and/or Treatment in Hungary. Cancers 2024, 16, 2917 Cancers doi: 10.3390/cancers16233964 Authors: Róza Ádány Attila Juhász Csilla Nagy Bernadett Burkali Péter Pikó Martin McKee Beatrix Oroszi In the original publication [...]

oncology
Corrigendum: Landscape of pediatric cancer treatment refusal and abandonment in the US: a qualitative study

Daniel J. Benedetti,Catherine M. Hammack-Aviran,Carolyn Diehl,Laura M. Beskow

DOI: https://doi.org/10.3389/fped.2024.1386784

IF: 3.569

2024-02-26

Frontiers in Pediatrics

Abstract:[This corrects the article DOI: 10.3389/fped.2022.1049661.].

pediatrics
Corrigendum to ‘Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics’ [Genes & Diseases10 (2023) 1367–1401]

Uttpal Anand,Abhijit Dey,Arvind K Singh Chandel,Rupa Sanyal,Amarnath Mishra,Devendra Kumar Pandey,Valentina De Falco,Arun Upadhyay,Ramesh Kandimalla,Anupama Chaudhary,Jaspreet Kaur Dhanjal,Saikat Dewanjee,Jayalakshmi Vallamkondu,José M Pérez de la Lastra,Arvind K. Singh Chandel,José M. Pérez de la Lastra

DOI: https://doi.org/10.1016/j.gendis.2024.101211

IF: 7.376

2024-01-01

Genes & Diseases

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2022.02.007.].

genetics & heredity,biochemistry & molecular biology
Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Thomas Morgan Hulen,Christina Friese,Nikolaj Pagh Kristensen,Joachim Stoltenborg Granhøj,Troels Holz Borch,Marlies J W Peeters,Marco Donia,Mads Hald Andersen,Sine Reker Hadrup,Inge Marie Svane,Özcan Met

DOI: https://doi.org/10.3389/fimmu.2024.1462081

2024-07-18

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1180997.].
Corrigendum: Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients

Xinhua Chen,Huimin Zhang,Minghao Wang,Hao Liu,Yanfeng Hu,Tian Lin,Hao Chen,Mingli Zhao,Tao Chen,Guoxin Li,Jiang Yu,Liying Zhao

DOI: https://doi.org/10.3389/fimmu.2023.1235273

IF: 7.3

2023-06-15

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.783695.].

immunology
Erratum: Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience

Frontiers Production Office

DOI: https://doi.org/10.3389/fendo.2024.1369692

IF: 6.055

2024-01-22

Frontiers in Endocrinology

Abstract:[This corrects the article DOI: 10.3389/fendo.2023.1270421.].

endocrinology & metabolism
Corrigendum: Development, Validation, and Visualization of A Web-Based Nomogram for Predicting the Recurrence-Free Survival Rate of Patients With Desmoid Tumors

Haotian Liu,Kai Huang,Tao Li,Tielong Yang,Zhichao Liao,Chao Zhang,Lijie Xiang,Yong Chen,Jilong Yang

DOI: https://doi.org/10.3389/fonc.2021.688620

IF: 4.7

2021-04-20

Frontiers in Oncology

Abstract:[This corrects the article .].

oncology
Corrigendum: Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer

Sen Miao,Gaoda Ju,Chonghua Jiang,Bing Xue,Lihua Zhao,Rui Zhang,Han Diao,Xingzhou Yu,Linlin Zhang,Xiaozao Pan,Hua Zhang,Lijuan Zang,Lei Wang,Tianhao Zhou

DOI: https://doi.org/10.3389/fmed.2024.1375203

IF: 3.9

2024-02-05

Frontiers in Medicine

Abstract:[This corrects the article DOI: 10.3389/fmed.2023.1167676.].

medicine, general & internal

Corrigendum: Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center

Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center

Corrigendum to "re: Pathologic Complete Responses, Long-Term Outcomes, and Recurrence Patterns in HER2-low Vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy: Several Issues about HER2 Expression and Neoadjuvant Chemotherapy in Breast Cancer" [eur J Cancer 180 (2023) 184-185].

Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors: A Propensity-Score Matched Cohort Study: Erratum

Erratum to "Additional biomarkers for pathological complete response in triple negative breast cancer"

Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Erratum: Preoperative immunological plasma markers TRAIL, CSF1, and TIE2 predict survival after resection for biliary tract cancer

Corrigendum: Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

Corrigendum to "Long recurrence-free survival of localized rectal melanoma after abdominoperineal resection in comparison to partial excision and highlighting the place of immunotherapy: A case report."

Corrigendum: Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellular carcinoma

Corrigendum: Whole-genome Landscape of Pancreatic Neuroendocrine Tumours.

Corrigendum: Predictive value of intratumoral-metabolic heterogeneity derived from 18F-FDG PET/CT in distinguishing microsatellite instability status of colorectal carcinoma

Correction: Ádány et al. Discrepancies Between the Spatial Distribution of Cancer Incidence and Mortality as an Indicator of Unmet Needs in Cancer Prevention and/or Treatment in Hungary. Cancers 2024, 16, 2917

Corrigendum: Landscape of pediatric cancer treatment refusal and abandonment in the US: a qualitative study

Corrigendum to ‘Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics’ [Genes & Diseases10 (2023) 1367–1401]

Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Corrigendum: Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients

Erratum: Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience

Corrigendum: Development, Validation, and Visualization of A Web-Based Nomogram for Predicting the Recurrence-Free Survival Rate of Patients With Desmoid Tumors

Corrigendum: Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer